National Institutes of Health: Tongue Neoplasms trials

The registry lists 15 Tongue Neoplasms studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 5Phase 2 10Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Rapamycin Therapy in Head and Neck Squamous Cell CarcinomaCompletedNCT01195922Phase 1/2Results posted
• Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabCompletedNCT00939627Phase 2Results posted
• Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT00588770Phase 3Results posted
• Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00513435Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00507767Phase 2Results posted
• Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral LeukoplakiaCompletedNCT00330382Phase 2Results posted
• Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT00103259Phase 2Results posted
• Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00906360Phase 1
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00114283Phase 2
• S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00096512Phase 2
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or PharynxCompletedNCT00064103Phase 1/2
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerCompletedNCT00049283Phase 1
• Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and NeckCompletedNCT00033618Phase 2